Measurable residual disease in multiple myeloma: ready for clinical practice?

by Leire Burgos, Noemi Puig, Maria-Teresa Cedena, María-Victoria Mateos, Juan José Lahuerta, Bruno Paiva, Jesús F. San-Miguel
Published 2020-06-01

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.

by Maria-Teresa Cedena, Estela Martin-Clavero, Sandy Wong, Nina Shah, Natasha Bahri, Rafael Alonso, Carmen Barcenas, Antonio Valeri, Johny Salazar Tabares, Jose Sanchez-Pina, Clara Cuellar, Thomas Martin, Jeffrey Wolf, Juan-Jose Lahuerta, Joaquin Martinez-Lopez
Published 2020-01-01

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

by Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado, Santiago Barrio, Thomas Martin, Maria Teresa Cedena, Jeffrey Wolf
Published 2021-08-01

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma

by Alejandra Ortiz-Ruiz, Yanira Ruiz-Heredia, María Luz Morales, Pedro Aguilar-Garrido, Almudena García-Ortiz, Antonio Valeri, Carmen Bárcena, Rosa María García-Martin, Vanesa Garrido, Laura Moreno, Alicia Gimenez, Miguel Ángel Navarro-Aguadero, María Velasco-Estevez, Eva Lospitao, María Teresa Cedena, Santiago Barrio, Joaquín Martínez-López, María Linares, Miguel Gallardo
Published 2021-04-01